The decrease of $1,700,000 was primarily attributable to the $10,000,000 purchase of the rights to PDS-one EDC in 20 22, partially offset by an increase in clinical costs of $6,100,000 and an increase in personnel cost of $2,100,000 As a reminder, we entered into an exclusive worldwide license for PDS-one ADC in late 2022 for consideration of $5,000,000 in cash $5,000,000 in company shares. General and administrative expenses for the year ended December 31, 2023 increased to $15,300,000 compared to $12,200,000 for the year ended December 31, 2022. The $3,100,000 increase was primarily attributable to an increase in personnel costs of 1,500,000 dollars and an increase in professional fees of $1,600,000 Total operating expenses for the year ended December 31, 2023 were $43,000,000 an increase of approximately 3.3% compared to $41,700,000 in total operating expenses for the year ended December 31, 2022. Net interest expense increased to $1,300,000 for the year ended December 31, 2023, compared to $400,000 for the year ended December 31, 2022. This change was due to higher interest rate interest expense related to the company's notes payable, which was partially offset by higher interest income on our bank deposits.